Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Nguyen, Dung H ^a,b   Cho, Newton ^a,b   Satkunendrarajah, Kajana ^b   Austin, James W ^a,b   Wang, Jian ^a,b,c,d   Fehlings, Michael G ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Functional recovery; Immuno modulatory; Immunoglobulin G; Inflammation; Spinal cord injury

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CELL LEVEL; CELLULAR DISTRIBUTION; CERVICAL SPINAL CORD INJURY; CLIP; COGNITION; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EVOKED MUSCLE RESPONSE; FEMALE; HISTOPATHOLOGY; NERVE COMPRESSION; NERVE CONDUCTION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT; RISK REDUCTION; TISSUE PRESERVATION;

EID: 84866478622     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-224     Document Type: Article

References (63)

1. Hall ED, Yonkers PA, Horan KL. Correlation between attenuation of posttraumatic spinal cord ischemia and preservation of tissue vitamin E by the 21-aminosteroid u74006F: evidence for an in vivo antioxidant mechanism. J Neurotrauma 1989, 6:169-176. 10.1089/neu.1989.6.169, 2810381.
2. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991, 75:15-26. 10.3171/jns.1991.75.1.0015, 2045903.
3. Kwon BK, Sekhon LH, Fehlings MG. Emerging repair, regeneration, and translational research advances for spinal cord injury. Spine 2010, Suppl. 1:S263-S270.
4. Blight AR. Delayed demyelination, macrophage invasion: a candidate for " secondary" cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985, 2:299-315.
5. Young W. Secondary injury mechanisms in acute spinal cord injury. J Emerg Med 1993, 11:13-22.
6. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004, 4:451-464. 10.1016/j.spinee.2003.07.007, 15246307.
7. Donnelly D, Popovich P. Inflammation and its role in neuroprotection, axonal regeneration and function recovery after spinal cord injury. Exp Neurol 2007, 209:378-388. 2692462, 17662717.
8. Profyris C, Cheema S, Zang DW, Azari M, Boyle K, Petratos S. Dengerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004, 15:415-436. 10.1016/j.nbd.2003.11.015, 15056450.
9. Cetin A, Nas K, Buyukbayram H, Ceviz A, Olmez G. The effects of systematically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats. Eur Spine J 2006, 15:1539-1544. 10.1007/s00586-006-0091-2, 16547753.
10. Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992, 76:13-22. 10.3171/jns.1992.76.1.0013, 1727150.
11. Oudega M, Vargas CG, Weber AB, Kleitman N, Bunge MB. Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur J Neurosci 1999, 11:2453-2464. 10.1046/j.1460-9568.1999.00666.x, 10383635.
12. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006, 97:1314-1326. 10.1111/j.1471-4159.2006.03799.x, 16638021.
13. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003, 20:1017-1027. 10.1089/089771503770195867, 14588118.
14. Stirling DP, Khodarahmi K, Liu J, McPhail LT, Mcbride CB, Steeves JD, Ramer MS, Tetzlaff W. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004, 24:2182-2190. 10.1523/JNEUROSCI.5275-03.2004, 14999069.
15. Gris D, Marsh D, Oatway M, Chen Y, Hamilton E, Dekaban G, Weaver L. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci 2004, 24:4043-4051. 10.1523/JNEUROSCI.5343-03.2004, 15102919.
16. Bao F, Chen Y, Schneider KA, Weaver LC. An integrin inhibiting molecule decreases oxidative damage and improves neurological function after spinal cord injury. Exp Neurol 2008, 214:160-167. 10.1016/j.expneurol.2008.09.006, 18926823.
17. Bao F, Chen Y, Dekaban GA, Weaver LC. An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats. J Neurochem 2004, 90:1194-1204. 10.1111/j.1471-4159.2004.02580.x, 15312174.
18. Tonai T, Shiba K, Taketani Y, Ohmoto Y, Murata K, Muraguchi M, Ohsaki H, Takeda E, Nishisho T. A neutrophil elastase inhibitor (ONO-5046) reduces neurologic damage after spinal cord injury in rats. J Neurochem 2001, 78:1064-1072. 10.1046/j.1471-4159.2001.00488.x, 11553680.
19. Ghasemlou D, Bouhy D, Yang J, Lopez-vales R, Haber M, Thuraisingam T, He G, Razioch D, Ding A, David S. Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain 2010, 133:126-138. 10.1093/brain/awp304, 2801328, 20047904.
20. Popovich PG, Guan Z, Wei P, Huitinga I, van Roojen N, Stokes BT. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol 1999, 158:351-365. 10.1006/exnr.1999.7118, 10415142.
21. Kwon B, Okon E, Hillyer J, Mann C, Baptiste D, Weaver L, Fehlings MG, Tetzlaff W. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 2010, 27:1-44. 10.1089/neu.2009.0948, 2924783, 19698073.
22. Bracken MB, Shepard MJ, Holdford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VK, Wagner F, Wilberger JW, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-1604. 10.1001/jama.1997.03540440031029, 9168289.
23. Hurlbert RJ. Methylprednisolone for acture spinal cord injury: an inappropriate standard of care. J Neurosurg 2000, 93:1-7. 10.3171/jns.2000.93.1.0001, 11153474.
24. Hurlbert RJ, Moulton R. Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and position statement. Can J Neurol Sci 2002, 29:236-239.
25. Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006, Suppl. 5:V/18-V/24.
26. Arumugam T, Tang S, Lathia J, Cheng A, Mughal MR, Chigurupati S, Magnus T, Chan SL, Jo DG, Ouyang X, Fairlie DP, Granger DN, Vortmeyer A, Basta M, Mattson MP. Intravenous Immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2008, 104:14104-14109.
27. Soelberg Sorensen P. Intravenous polyclonal human immunoglobulins in mutiple sclerosis. Neurodegener Dis 2008, 5:8-15. 10.1159/000109932, 18075269.
28. Gok B, Sciubba D, Okutan O, Beskonakli E, Palaoglu S, Erdarmar H, Sargon M. Immunomodulation of acute experimental spinal cord injury with human immunoglobulin G. J Clin Neurosci 2009, 16:549-553. 10.1016/j.jocn.2008.04.024, 19200733.
29. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 1978, 10:38-43.
30. Fehlings MG, Tator CH. The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp Neurol 1995, 132:220-228. 10.1016/0014-4886(95)90027-6, 7789460.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951, 193:265-275.
32. Peterson GL. Review of the folin phenol protein quantification method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 1979, 100:201-220. 10.1016/0003-2697(79)90222-7, 393128.
33. Rivlin AS, Tator CH. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg 1977, 47:577-581. 10.3171/jns.1977.47.4.0577, 903810.
34. Midha R, Fehlings MG, Tator CH, Saint-Cyr JA, Guha A. Assessment of spinal cord injury by counting corticospinal and rubrospinal neurons. Brain Res 1987, 410:299-308. 10.1016/0006-8993(87)90328-3, 3594239.
35. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12:1-21. 10.1089/neu.1995.12.1, 7783230.
36. Nashimi R, Imahura H, Tator CH, Fehlings MG. Serial recording of somatosensory and myoelectric motor evoked potentials: role in assessing functional recovery after graded spinal cord injury in the rat. J Neurotrauma 1997, 14:151-159. 10.1089/neu.1997.14.151, 9104932.
37. Pineau I, Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol 2007, 500:267-285. 10.1002/cne.21149, 17111361.
38. Pineau I, Sun L, Bastien D, Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-depdent fashion. Brain Behav Immun 2009, 24:540-553.
39. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, Naruo M, Okabe H, Takatsuki K. Role of neutrophils in spinal cord injury in the rat. Neuroscience 1997, 79:1177-1182. 10.1016/S0306-4522(97)00011-0, 9219976.
40. Bao F, Chen Y, Dekaban GA, Weaver LC. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J Neurochem 2004, 88:1335-1344. 10.1046/j.1471-4159.2003.02240.x, 15009633.
41. Abbas A, Lichtman AH, Pober JS. (Eds): Cellular and Molecular Immunology 2000, WB Saunders Company, Philadelphia, PA, 4.
42. Clark RS, Kochanek PM, Schwarz MA, Schiding JK, Turner DS, Chen M, Carlos TM, Watkins SC. Inducible nitric oxide synthase expression in the cerebrovascular smooth muscle and neutrophils after traumatic brain injury in immature rats. Pediatr Res 1996, 39:784-790. 10.1203/00006450-199605000-00007, 8726229.
43. Beckman J, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990, 87:1620-1624. 10.1073/pnas.87.4.1620, 53527, 2154753.
44. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995, 16:21-26. 10.1016/0167-5699(95)80066-2, 7880385.
45. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, Pasquale-Styles M, Dietrich WD. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269. 10.1093/brain/awl296, 17071951.
46. Noble L, Donovan F, Igarashi T, Goussev S, Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002, 22:7526-7535. 2792199, 12196576.
47. Bainton D, Farquhar M. Differences in enzyme content of azurophilic and specific granules of polymorphonuclear leukocytes II. Cytochemistry and electron microscopy of bone marrow cells. J Cell Biol 1968, 39:299-317. 10.1083/jcb.39.2.299, 2107532, 5692583.
48. Bartholdi D, Schwab M. Expresion of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci 1997, 9:1422-1438. 10.1111/j.1460-9568.1997.tb01497.x, 9240400.
49. Yang L, Blumbers P, Jones N, Manavis J, Sarvestani G, Ghabriel M. Early expression and cellular localization of proinflammatory cytokines interleukin-1B, interleukin-6, and tumour necrosis factor-a in human traumatic spinal cord injury. Spine 2004, 29:966-971. 10.1097/00007632-200405010-00004, 15105666.
50. Wang C, Olschowka J, Wrathall J. Increase of interleukin-1B mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res 1997, 759:190-196. 10.1016/S0006-8993(97)00254-0, 9221936.
51. Allan S, Rothwell N. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744. 10.1038/35094583, 11584311.
52. Wong D, Doronvini-Zis K. Expression of vascular cell adhesion molecule-1 (VCAM-1) by human brain microvessel endothelial cells in primary culture. Microvasc Res 1995, 49:325-339. 10.1006/mvre.1995.1028, 7543972.
53. Wong D, Doronvini-Zis K. Regulation by cytokines and lippopolysaccharide of E-selectin expression by human brain microvessel endothelia cells in primary culture. J Neuropathol Exp Neurol 1996, 55:225-235. 10.1097/00005072-199602000-00011, 8786381.
54. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6:315-325. 10.1016/S1074-7613(00)80334-9, 9075932.
55. Penkowa M, Moos T, Carrasco J, Hanne H, Molinero A, Bluethmann H, Hidalgo J. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia 1999, 25:343-357. 10.1002/(SICI)1098-1136(19990215)25:4<343::AID-GLIA4>3.0.CO;2-V, 10028917.
56. Cuzzocrea S, de Sarro G, Costantino G, Mazzon E, Laura R, Ciriaco E, de Sarro A. Caputi AP Role of interleukin-6 in a non-septic shock model induced by zymosan. Eur Cytokine Netw 1999, 10:191-203.
57. Genovesse T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Esposito E, Bramanti P, Cuzzocrea S. TNF-α blockade in a mouse model of SCI: Evidence for improved outcome. Shock 2008, 29:32-41.
58. Campbell S, Wilcockson D, Butchart A, Perry H, Anthony D. Altered chemokine expression in the spinal cord and brain contributes to differential interleukin-1B-induced neutrophil recruitment. J Neurochem 2002, 83:432-441. 10.1046/j.1471-4159.2002.01166.x, 12423253.
59. Lacroix S, Chang L, Rose-John S, Tuszynski M. Delivery of Hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infilration and inhibits axonal growth. J Comp Neurol 2002, 454:213-228. 10.1002/cne.10407, 12442313.
60. Schnell L, Fearn S, Schwab ME, Perry VH, Anthony DC. Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol 1999, 58:245-254. 10.1097/00005072-199903000-00004, 10197816.
61. Mukaino M, Nakamura M, Yamada O, Okada S, Morikawa S, Renault-Mihara F, Iwanami A, Ikegami T, Ohsugi Y, Tsuji O, Katoh H, Matsuzaki Y, Toyama Y, Liu M, Okano H. Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp Neurol 2010, 224:403-414. 10.1016/j.expneurol.2010.04.020, 20478301.
62. Okada S, Nakamura M, Mikami Y, Shimazaki T, Mihara M, Ohsugi Y, Iwamoto Y, Yoshizaki K, Kishimoto T, Toyama Y, Okano H. Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. J Neurosci Res 2004, 76:265-276. 10.1002/jnr.20044, 15048924.
63. Taoka Y, Okajima K, Murakami K, Johno M, Naruo M. Role of neutrophil elastase in compression-induced spinal injury in rats. Brain Res 1998, 799:264-269. 10.1016/S0006-8993(98)00459-4, 9675307.